Company Metrics

• 30.93 P/E
• 1.72 P/S
• 2.64 P/B
• 1.081 EPS
• 11.38% Cash ROIC
• 0.57 Cash Ratio
• 0 / 0% Dividend
• 319,385.00 Avg. Vol.
• 60.55M Shares
• 2.023B Market Cap.

Company Description

ICON plc, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries primarily in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support clinical development from compound selection to Phase I to IV clinical studies. The company's clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, patient safety monitoring, clinical data management, interactive voice response, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, and health economics. Its clinical research services also comprise strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, medical imaging, contract staffing, and electronic endpoint adjudication. In addition, the company offers various laboratory services, including sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development. It has an alliance agreement with ACRONET Corp.; and a strategic alliance with Boston Clinical Research Institute. The company was founded in 1990 and is headquartered in Dublin, Ireland.
less

ICON plc, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries primarily in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support clinical development from compound selection to Phase I to IV clinical studies. The company's c...
more

News